BRAFV600E mutation, BRAF-activated long non-coding RNA and miR-9 expression in papillary thyroid carcinoma, and their association with clinicopathological features

Abstract

Background: The incidence of thyroid cancer is increasing worldwide. This study investigated the association of Btype RAF kinase (BRAF) V600E mutation status, the expression of BRAF-activated long non-coding RNA (BANCR) and microRNA miR-9, and the clinicopathological features of papillary thyroid carcinoma (PTC). Methods: Clinicopathological data for PTC patients (n = 51) diagnosed and treated between 2018 and 2019 were collected. Carcinoma and adjacent normal tissue samples were analyzed for the presence of the BRAF V600E mutation and/or expression of BANCR and miR-9. Results: Larger tumor, higher rate of bilateral tumors and multifocality, extracapsular invasion, and lateral lymph node metastasis (LNM) were observed in PTC patients with BRAF V600E mutation. Patients with higher BANCR expression had a higher rate of extracapsular invasion and lateral LNM in carcinoma tissue and a lower frequency of bilateral tumors and multifocality in normal adjacent tissue. Patients with higher miR-9 expression had a lower rate of central and lateral LNM in carcinoma tissue and higher rates of bilateral tumor location and multifocality in normal adjacent tissue. Patients with BRAF V600E mutation have a higher rate of BANCR overexpression and tended to have a lower rate of miR-9 overexpression (P = 0.057), and a negative association was observed between BANCR and miR-9 expression in carcinoma tissue.

Predicting factors of central lymph node metastasis and BRAFV600E mutation in Chinese population with papillary thyroid carcinoma

“…With the emerging understanding of molecular genetics in thyroid cancer, several specific molecular events in PTC have been identified that assist in the diagnosis and prognostic evaluation of PTC patients [11][12][13]. The Btype Raf kinase (BRAF) V600E mutation was found to be the most important candidate biomarker for PTC diagnosis because of its high prevalence and high specificity [14,15].…”

Dysregulation of microRNAs as the risk factor of lymph node metastasis in papillary thyroid carcinoma: systematic review

“…The 2 reviewers were in agreement regarding study eligibility. The earliest study was published in May 2010 [15] and the latest in June 2020 [16]. The included studies were from 7 countries: China (n = 20), Serbia (n = 2), Lithuania (n = 1), South Korea (n = 1), Taiwan (n = 1), Turkey (n = 1), and the USA (n = 1).…”

“…For initial genome screening, 4 studies [15,[20][21][22] performed microarray, and 1 study [17] used Solexa sequencing, followed by qRT-PCR to validate results. However, of all the rest of the studies 21 performed qRT-PCR [16,19,[23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41]] and 1 study performed northern blotting [18] to quantify miRNA expression for a priori selected miRNAs from the literature.…”

“…Analysing associations between miRNA and LNM, one study [17] used Pearson's correlation coefficient to correlate miRNAs from blood and tissue, and 2 studies [26,33] used multivariate logistic regression to assess independent predictors for LNM. Six studies divided miRNA expression into low/high groups based on mean or median values, and then compared those groups as categorical variables using the chi-square test to assess differences between miRNA expression and LNM status [16,[28][29][30][31]37]. Four studies [32,38,39,41]…”

Role of lncRNA BANCR in Human Cancers: An Updated Review

“…Contrary to the formerly mentioned study, the presence of BRAF V600E mutation has been associated with higher probability of BANCR up-regulation. Patients with BRAF V600E mutation, over-expression of BANCR and down-regulation of miR-9 have been shown to need earlier surgical management particularly total thyroidectomy in primary surgery in order to decrease tumor recurrence ( Shi et al, 2020 ). Supplementary Table 2 demonstrates the observed effects of BANCR dysregulation in clinical settings.…”